Your session is about to expire
← Back to Search
PD-1 Blockade + Chemoradiation for Cancer
Study Summary
This trial is testing a new drug to see if it, combined with other standard treatments, is effective against a type of solid tumor. The trial will also monitor for side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently on medication for an infection.My colorectal cancer is causing symptoms like blockage in my bowel.You are allergic to any of the ingredients or substances in TSR-042.I have not had cancer, except for non-melanoma skin cancer or cervical carcinoma in situ, in the last 5 years.I have not had major surgery or a significant injury in the last 28 days.My liver is functioning properly.My tumor shows signs of repair deficiency.I have a history of lung scarring or fibrosis.I haven't taken high-dose steroids or immunosuppressants in the last 7 days.I am not pregnant, breastfeeding, nor planning to conceive or father a child during the trial and for 150 days after.I have had radiation, chemotherapy, or surgery for my tumor.I am 18 years old or older.My blood clotting function is normal.My kidney function, measured by creatinine or GFR, is within the normal range.My blood clotting tests are normal or managed with medication.My cancer is confirmed and has spread locally but not to distant parts.I do not have any severe health or mental conditions that would prevent me from safely participating in the study.I am fully active or can carry out light work.I am not pregnant and agree to use birth control during and after the study.My organ functions are within normal ranges as required.I have not received a live vaccine in the last 30 days.I have been on a stable dose of corticosteroids for at least 4 weeks.I have previously received treatment targeting immune checkpoints.I have an autoimmune disease that needed strong medication in the last 2 years.I am not currently on any other cancer treatments or experimental drugs.My cancer has not spread to distant parts of my body.I had a severe reaction to previous immunotherapy, except for minor lab changes.I have been diagnosed with HIV.My cancer has spread or come back.I am over 45 and have not had a period for more than a year.My blood counts are within normal ranges.I have had a hysterectomy, both ovaries removed, or my tubes tied, with documentation.My solid tumor is typically treated with therapy before surgery.
- Group 1: Cohort 2
- Group 2: Cohort 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
In how many different places can people participate in this trial?
"There are 11 enrolment sites for this clinical trial, including Lehigh Valley Health Network (Data Collection Only) in Allentown, Pennsylvania, Memorial Sloan Kettering Monmouth - Limited Protocol Activities in Middletown, New jersey and Memoral Sloan Kettering Westchester - Limited Protocol Activities in Harrison, New york."
Are there any limitations to who can sign up for this particular clinical trial?
"Yes, this research is currently looking for volunteers to participate. The trial was first advertised on December 11th 2019 and has since been updated on October 12th 2020."
What else is known about TSR-042 from past research?
"TSR-042 was first trialled at Withington Hospital in 2005. So far, 555 completed trials have been conducted. Currently, there are 393 ongoing studies recruiting participants, many of which based in Allentown, Pennsylvania."
What are the benefits of TSR-042?
"TSR-042 is an effective medication for patients suffering from metastatic colorectal carcinoma, pancreatic endocrine carcinoma, and refractory ovarian cancer."
Has the FDA cleared TSR-042 for general use?
"Because TSR-042 is only in Phase 2 trials, there is not yet enough data to support its efficacy. However, there is some evidence that suggests it is safe, so it received a score of 2."
How many people are participating in this clinical trial?
"In order to gather the data required, 51 individuals that meet the pre-determined inclusion criteria are needed to participate. These chosen patients can come from different hospitals, such as Lehigh Valley Health Network (Data Collection Only) in Allentown, Pennsylvania and Memorial Sloan Kettering Monmouth - Limited Protocol Activities in Middletown, New jersey."
Share this study with friends
Copy Link
Messenger